4.5 Article

Surrogate endpoints and FDA's accelerated approval process

期刊

HEALTH AFFAIRS
卷 24, 期 1, 页码 67-78

出版社

PROJECT HOPE
DOI: 10.1377/hlthaff.24.1.67

关键词

-

资金

  1. NIAID NIH HHS [R37 AI 29168] Funding Source: Medline
  2. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029168] Funding Source: NIH RePORTER

向作者/读者索取更多资源

There is interest in approaches allowing more rapid availability of new interventions, particularly for diseases providing risks of death or serious illness. The accelerated-approval regulatory process is intended to address this need by allowing marketing of interventions shown to have strong effects on measures of biological activity, if those measures are potential surrogates for true measures of tangible clinical benefit. To use surrogate endpoints and the accelerated-approval process, challenging issues must be addressed to avoid compromising what is truly in the best interest of public health: the reliable as well as timely evaluation of an intervention's safety and efficacy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据